Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet?

Critical reviews in oncology/hematology - 1 Nov 2016

Bronte Giuseppe, Incorvaia Lorena, Rizzo Sergio, Passiglia Francesco, Galvano Antonio, Rizzo Fabio, Rolfo Christian, Fanale Daniele, Listì Angela, Natoli Clara, Bazan Viviana, Russo Antonio

Abstract excerpt

Malignant pleural mesothelioma (MPM) is an aggressive tumor of the pleura with a poor prognosis. The most active first-line regimens are platinum compounds and pemetrexed. There is no standard second-line treatment in MPM. Advances in the understanding of tumor molecular biology have led to the development of several targeted treatments, which have been evaluated in clinical trials. Unfortunately none of the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Mesothelioma

Share to Mesothelioma, Malignant

Share to Molecular Targeted Therapy

Share to Mutation

Share to Pleural Neoplasms

Source

Identifiers

PMID: 27823648
DOI: 10.1016/j.critrevonc.2016.08.011

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet?PMID 27823648Read ↗

Malignant pleural mesothelioma: Genome-wide expression patterns reflecting general resistance mechanisms and a proposal of novel targetsSemantic proximity Read ↗

Molecular Resistance Fingerprint of Pemetrexed and Platinum in a Long-Term Survivor of MesotheliomaSemantic proximity Read ↗

Intrapleural injection of Folactis promotes regression of malignant pleural effusion: a case of malignant pleural mesothelioma and the review of literaturesSemantic proximity Read ↗

The Molecular Basis of Malignant Pleural MesotheliomaSemantic proximity Read ↗

Upregulation of Thymidylate Synthase Induces Pemetrexed Resistance in Malignant Pleural MesotheliomaSemantic proximity Read ↗

ERCC1, MLH1, MSH2, MSH6, and βIII-Tubulin: Resistance Proteins Associated With Response and Outcome to Platinum-based Chemotherapy in Malignant Pleural MesotheliomaSemantic proximity Read ↗

The role of MDM2 amplification and overexpression in therapeutic resistance of malignant tumorsSemantic proximity Read ↗

Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitroSemantic proximity Read ↗

Multimodality treatment of malignant pleural mesotheliomaSemantic proximity Read ↗

Alterations in BAP1 Are Associated with Cisplatin Resistance through Inhibition of Apoptosis in Malignant Pleural MesotheliomaSemantic proximity Read ↗

Impact of metallothionein-knockdown on cisplatin resistance in malignant pleural mesotheliomaSemantic proximity Read ↗

Genome-wide silencing screen in mesothelioma cells reveals that loss of function of BAP1 induces chemoresistance to ribonucleotide reductase inhibition: implication for therapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.